Cargando…

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the i...

Descripción completa

Detalles Bibliográficos
Autores principales: van Doesum, Jaap A., Salmanton-García, Jon, Marchesi, Francesco, Di Blasi, Roberta, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Van Praet, Jens, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, De Ramón-Sánchez, Cristina, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almeida, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin, Hernández-Rivas, José-Ángel, Gomes da Silva, Maria, Fernández, Noemí, Espigado, Ildefonso, Drgoňa, Ľuboš, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, Maria, Blennow, Ola, Wolf, Dominik, van Anrooij, Bjorn, Nunes Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Liévin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie K., García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, van Meerten, Tom, Cornely, Oliver A., Pagano, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112941/
https://www.ncbi.nlm.nih.gov/pubmed/37058479
http://dx.doi.org/10.1182/bloodadvances.2022009578
_version_ 1785027720840740864
author van Doesum, Jaap A.
Salmanton-García, Jon
Marchesi, Francesco
Di Blasi, Roberta
Falces-Romero, Iker
Cabirta, Alba
Farina, Francesca
Besson, Caroline
Weinbergerová, Barbora
Van Praet, Jens
Schönlein, Martin
López-García, Alberto
Lamure, Sylvain
Guidetti, Anna
De Ramón-Sánchez, Cristina
Batinić, Josip
Gavriilaki, Eleni
Tragiannidis, Athanasios
Tisi, Maria Chiara
Plantefeve, Gaëtan
Petzer, Verena
Ormazabal-Vélez, Irati
Marques de Almeida, Joyce
Marchetti, Monia
Maertens, Johan
Machado, Marina
Kulasekararaj, Austin
Hernández-Rivas, José-Ángel
Gomes da Silva, Maria
Fernández, Noemí
Espigado, Ildefonso
Drgoňa, Ľuboš
Dragonetti, Giulia
Metafuni, Elisabetta
Calbacho, Maria
Blennow, Ola
Wolf, Dominik
van Anrooij, Bjorn
Nunes Rodrigues, Raquel
Nordlander, Anna
Martín-González, Juan-Alberto
Liévin, Raphaël
Jiménez, Moraima
Gräfe, Stefanie K.
García-Sanz, Ramón
Córdoba, Raúl
Rahimli, Laman
van Meerten, Tom
Cornely, Oliver A.
Pagano, Livio
author_facet van Doesum, Jaap A.
Salmanton-García, Jon
Marchesi, Francesco
Di Blasi, Roberta
Falces-Romero, Iker
Cabirta, Alba
Farina, Francesca
Besson, Caroline
Weinbergerová, Barbora
Van Praet, Jens
Schönlein, Martin
López-García, Alberto
Lamure, Sylvain
Guidetti, Anna
De Ramón-Sánchez, Cristina
Batinić, Josip
Gavriilaki, Eleni
Tragiannidis, Athanasios
Tisi, Maria Chiara
Plantefeve, Gaëtan
Petzer, Verena
Ormazabal-Vélez, Irati
Marques de Almeida, Joyce
Marchetti, Monia
Maertens, Johan
Machado, Marina
Kulasekararaj, Austin
Hernández-Rivas, José-Ángel
Gomes da Silva, Maria
Fernández, Noemí
Espigado, Ildefonso
Drgoňa, Ľuboš
Dragonetti, Giulia
Metafuni, Elisabetta
Calbacho, Maria
Blennow, Ola
Wolf, Dominik
van Anrooij, Bjorn
Nunes Rodrigues, Raquel
Nordlander, Anna
Martín-González, Juan-Alberto
Liévin, Raphaël
Jiménez, Moraima
Gräfe, Stefanie K.
García-Sanz, Ramón
Córdoba, Raúl
Rahimli, Laman
van Meerten, Tom
Cornely, Oliver A.
Pagano, Livio
author_sort van Doesum, Jaap A.
collection PubMed
description Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19–caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
format Online
Article
Text
id pubmed-10112941
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-101129412023-04-19 Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey van Doesum, Jaap A. Salmanton-García, Jon Marchesi, Francesco Di Blasi, Roberta Falces-Romero, Iker Cabirta, Alba Farina, Francesca Besson, Caroline Weinbergerová, Barbora Van Praet, Jens Schönlein, Martin López-García, Alberto Lamure, Sylvain Guidetti, Anna De Ramón-Sánchez, Cristina Batinić, Josip Gavriilaki, Eleni Tragiannidis, Athanasios Tisi, Maria Chiara Plantefeve, Gaëtan Petzer, Verena Ormazabal-Vélez, Irati Marques de Almeida, Joyce Marchetti, Monia Maertens, Johan Machado, Marina Kulasekararaj, Austin Hernández-Rivas, José-Ángel Gomes da Silva, Maria Fernández, Noemí Espigado, Ildefonso Drgoňa, Ľuboš Dragonetti, Giulia Metafuni, Elisabetta Calbacho, Maria Blennow, Ola Wolf, Dominik van Anrooij, Bjorn Nunes Rodrigues, Raquel Nordlander, Anna Martín-González, Juan-Alberto Liévin, Raphaël Jiménez, Moraima Gräfe, Stefanie K. García-Sanz, Ramón Córdoba, Raúl Rahimli, Laman van Meerten, Tom Cornely, Oliver A. Pagano, Livio Blood Adv Clinical Trials and Observations Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19–caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729. The American Society of Hematology 2023-04-18 /pmc/articles/PMC10112941/ /pubmed/37058479 http://dx.doi.org/10.1182/bloodadvances.2022009578 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Trials and Observations
van Doesum, Jaap A.
Salmanton-García, Jon
Marchesi, Francesco
Di Blasi, Roberta
Falces-Romero, Iker
Cabirta, Alba
Farina, Francesca
Besson, Caroline
Weinbergerová, Barbora
Van Praet, Jens
Schönlein, Martin
López-García, Alberto
Lamure, Sylvain
Guidetti, Anna
De Ramón-Sánchez, Cristina
Batinić, Josip
Gavriilaki, Eleni
Tragiannidis, Athanasios
Tisi, Maria Chiara
Plantefeve, Gaëtan
Petzer, Verena
Ormazabal-Vélez, Irati
Marques de Almeida, Joyce
Marchetti, Monia
Maertens, Johan
Machado, Marina
Kulasekararaj, Austin
Hernández-Rivas, José-Ángel
Gomes da Silva, Maria
Fernández, Noemí
Espigado, Ildefonso
Drgoňa, Ľuboš
Dragonetti, Giulia
Metafuni, Elisabetta
Calbacho, Maria
Blennow, Ola
Wolf, Dominik
van Anrooij, Bjorn
Nunes Rodrigues, Raquel
Nordlander, Anna
Martín-González, Juan-Alberto
Liévin, Raphaël
Jiménez, Moraima
Gräfe, Stefanie K.
García-Sanz, Ramón
Córdoba, Raúl
Rahimli, Laman
van Meerten, Tom
Cornely, Oliver A.
Pagano, Livio
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
title Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
title_full Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
title_fullStr Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
title_full_unstemmed Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
title_short Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
title_sort impact of sars-cov-2 vaccination and monoclonal antibodies on outcome post–cd19-directed car t-cell therapy: an epicovideha survey
topic Clinical Trials and Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112941/
https://www.ncbi.nlm.nih.gov/pubmed/37058479
http://dx.doi.org/10.1182/bloodadvances.2022009578
work_keys_str_mv AT vandoesumjaapa impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT salmantongarciajon impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT marchesifrancesco impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT diblasiroberta impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT falcesromeroiker impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT cabirtaalba impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT farinafrancesca impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT bessoncaroline impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT weinbergerovabarbora impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT vanpraetjens impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT schonleinmartin impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT lopezgarciaalberto impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT lamuresylvain impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT guidettianna impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT deramonsanchezcristina impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT batinicjosip impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT gavriilakieleni impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT tragiannidisathanasios impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT tisimariachiara impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT plantefevegaetan impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT petzerverena impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT ormazabalvelezirati impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT marquesdealmeidajoyce impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT marchettimonia impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT maertensjohan impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT machadomarina impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT kulasekararajaustin impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT hernandezrivasjoseangel impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT gomesdasilvamaria impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT fernandeznoemi impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT espigadoildefonso impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT drgonalubos impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT dragonettigiulia impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT metafunielisabetta impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT calbachomaria impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT blennowola impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT wolfdominik impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT vananrooijbjorn impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT nunesrodriguesraquel impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT nordlanderanna impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT martingonzalezjuanalberto impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT lievinraphael impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT jimenezmoraima impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT grafestefaniek impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT garciasanzramon impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT cordobaraul impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT rahimlilaman impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT vanmeertentom impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT cornelyolivera impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey
AT paganolivio impactofsarscov2vaccinationandmonoclonalantibodiesonoutcomepostcd19directedcartcelltherapyanepicovidehasurvey